News
The initiative will provide practical insights into understanding of obesity pathophysiology and its management.
API and Eli Lilly launch nationwide CME programme to strengthen obesity care among indian physicians
The Obesity Gurukul initiative will train over 20,000 healthcare professionals across India through a hybrid education model ...
Lilly partners with API to launch ‘Obesity Gurukul’, a flagship continuing medical education program
Lilly partners with API to launch ‘Obesity Gurukul’, a flagship continuing medical education program: Our Bureau, Bengaluru Monday, July 14, 2025, 15:20 Hrs [IST] Eli Lilly an ...
An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...
Biocon aims to launch generic copies of the blockbuster weight-loss drug Wegovy in India and Canada within the next two years ...
GLP-1 anti-obesity medications are linked with improvements in testosterone levels and health outcomes for men with obesity ...
A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring to U.S. biopharma.
Eli Lilly is advancing its Phase 2 clinical trial to test LY3841136 for weight management in obese and overweight adults.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback